# PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC

> **NCT04809779** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 49 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04809779
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2023-12
- **Final completion:** 2024-03
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809779, "PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04809779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*